BR0015287A - Moléculas recombinantes de fusão - Google Patents
Moléculas recombinantes de fusãoInfo
- Publication number
- BR0015287A BR0015287A BR0015287-0A BR0015287A BR0015287A BR 0015287 A BR0015287 A BR 0015287A BR 0015287 A BR0015287 A BR 0015287A BR 0015287 A BR0015287 A BR 0015287A
- Authority
- BR
- Brazil
- Prior art keywords
- fusion molecules
- recombinant fusion
- production
- recombinant
- relates
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 3
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
"MOLéCULAS RECOMBINANTES DE FUSãO". Esta invenção refere-se a um processo para aumentar a produção de uma proteína em uma célula e mais particularmente pela produção em uma célula vegetal. Esta invenção também refere-se a complexos imunológicos recombinantes de fusão e mais particularmente à sua expressão em plantas. São divulgados constructos específicos que compreendem gp 120 fundido à região constante da cadeia pesada de um anticorpo ou parte do mesmo assim como o uso de tais constructos na geração de uma resposta imunológica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9926084.6A GB9926084D0 (en) | 1999-11-03 | 1999-11-03 | Recombinant fusion molecules |
PCT/GB2000/004216 WO2001032714A1 (en) | 1999-11-03 | 2000-11-03 | Recombinant fusion molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0015287A true BR0015287A (pt) | 2002-07-09 |
Family
ID=10863922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0015287-0A BR0015287A (pt) | 1999-11-03 | 2000-11-03 | Moléculas recombinantes de fusão |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1226178A1 (pt) |
JP (1) | JP2003512860A (pt) |
CN (1) | CN1399646A (pt) |
AU (1) | AU779719B2 (pt) |
BR (1) | BR0015287A (pt) |
CA (1) | CA2388955A1 (pt) |
GB (1) | GB9926084D0 (pt) |
HK (1) | HK1044956A1 (pt) |
WO (1) | WO2001032714A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006503545A (ja) * | 2002-02-14 | 2006-02-02 | ラター, ウィリアム ジェイ. | 処置される宿主における切断についてのキメラ分子 |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
TW200526778A (en) * | 2003-11-14 | 2005-08-16 | Sembiosys Genetics Inc | Methods for the production of apolipoproteins in transgenic plants |
JP2008521420A (ja) * | 2004-11-30 | 2008-06-26 | ノボ ノルディスク アクティーゼルスカブ | 抗体を産生する方法 |
US20090238822A1 (en) * | 2005-10-13 | 2009-09-24 | Virexx Medical Corp. | Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response |
GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
WO2010104747A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted vaccines |
DK2406286T3 (en) | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40 antibodies and uses thereof |
BR112012012563B1 (pt) * | 2009-11-18 | 2021-10-05 | Agriculture Victoria Services Pty Ltd | Método para produzir uma célula de planta transformada que expressa um gene de angiogenina e construto artificial capaz de permitir a expressão de um gene de angiogenina em uma célula de planta |
AU2015202777B2 (en) * | 2009-11-18 | 2017-09-14 | Agriculture Victoria Services Pty Ltd | Angiogenin expression in plants (2) |
JP7037884B2 (ja) | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | Hpv及びhpv関連疾患に対する新規のワクチン |
KR101596364B1 (ko) * | 2014-06-12 | 2016-02-23 | 중앙대학교 산학협력단 | 면역원성 복합 단백질을 생산하는 형질전환 식물체의 제조방법 및 이로부터 수득된 면역원성 복합 단백질 |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU660297B2 (en) * | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
EP0973933A1 (en) * | 1997-02-13 | 2000-01-26 | American National Red Cross | Immunological tolerance to hiv epitopes |
BR9908226A (pt) * | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
-
1999
- 1999-11-03 GB GBGB9926084.6A patent/GB9926084D0/en not_active Ceased
-
2000
- 2000-11-03 CN CN00814715A patent/CN1399646A/zh active Pending
- 2000-11-03 CA CA002388955A patent/CA2388955A1/en not_active Abandoned
- 2000-11-03 BR BR0015287-0A patent/BR0015287A/pt not_active IP Right Cessation
- 2000-11-03 EP EP00973028A patent/EP1226178A1/en not_active Withdrawn
- 2000-11-03 AU AU11584/01A patent/AU779719B2/en not_active Ceased
- 2000-11-03 WO PCT/GB2000/004216 patent/WO2001032714A1/en not_active Application Discontinuation
- 2000-11-03 JP JP2001535412A patent/JP2003512860A/ja active Pending
-
2002
- 2002-08-29 HK HK02106395.6A patent/HK1044956A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2003512860A (ja) | 2003-04-08 |
CN1399646A (zh) | 2003-02-26 |
GB9926084D0 (en) | 2000-01-12 |
EP1226178A1 (en) | 2002-07-31 |
WO2001032714A1 (en) | 2001-05-10 |
HK1044956A1 (zh) | 2002-11-08 |
AU779719B2 (en) | 2005-02-10 |
AU1158401A (en) | 2001-05-14 |
CA2388955A1 (en) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0015287A (pt) | Moléculas recombinantes de fusão | |
AR020048A1 (es) | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. | |
BR9713521A (pt) | ||
AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
NO963371L (no) | Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det | |
EP1427744A4 (en) | ANTIBODY EXPRESSION SYSTEM AND ASSEMBLY | |
ES2074042T3 (es) | Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores. | |
EA199800946A1 (ru) | Концентрированный препарат антител | |
WO2002002783A3 (en) | Expression vectors | |
ATE369346T1 (de) | Halogenpyrimidinylaryl(thio)ether als pestizide | |
DK0994728T3 (da) | Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf | |
PT76394B (fr) | Procede de preparation de nouveaux conjugues associant par liaison covalente une enzyme et un anticorps | |
IL172854A0 (en) | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations | |
BRPI0314373B8 (pt) | produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico | |
DE69434384D1 (de) | Metalkomplexbildner | |
ATE167670T1 (de) | N-alkylthiopolyaminderivate als radioprotektive mittel | |
BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
DK407987A (da) | Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer | |
DK369287D0 (da) | Immunotoksiner og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem | |
DE69317886D1 (de) | Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate | |
ATE98130T1 (de) | Kombination von angiotensin-converting-enzymehemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln. | |
ATE193534T1 (de) | Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden | |
ATE141415T1 (de) | Konjugate von antikörpern mit variablen domänen | |
BR9101117A (pt) | Produto que compreende um ou mais veiculos de material enzimatico e processo para distribuir um agente ativo a um sitio | |
SE8702734D0 (sv) | Monoclonal antibodies to pseudomonas aeruginosa flagella |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |